(BUSINESS WIRE)– Exact Sciences Corp. (NASDAQ:EXAS) today announced Norton Healthcare is the first healthcare system in Kentucky to offer Cologuard®, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Cologuard makes it easy for average risk patients 50 years and older to get screened at their convenience and in the privacy and comfort of their own home without having to worry about taking time off work to prepare for an invasive procedure… Read more »
Shares of Exact Sciences Corp opened today at $28.44 and are currently trading down at $27.22. EXAS has a 1-year high of $29.97 and a 1-year low of $10.69. The stock’s 50-day moving average is $27.48 and it’s 200-day moving average is $22.35.
On the ratings front, Exact Sciences Corp has been the subject of a number of recent research reports. In a report issued on January 23, Mizuho analyst Peter Lawson reiterated a Buy rating on EXAS, with a price target of $30, which implies an upside of 5.5% from current levels. Separately, on January 22, Roth Capital’s Chris Lewis reiterated a Buy rating on the stock and has a price target of $30.
In total, one research analyst has assigned a Hold rating and 6 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $28.44 which is 2.0% above where the stock opened today.
Exact Sciences Corp is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.